News | April 01, 2022
Oragnon enters global licencing agreement with Dare Biosciences
An estimated 21 million American women experience BV
An estimated 21 million American women experience BV
The science leader comes with a rich experience in the employment testing industry
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
The facility will produce 150 million vaccine doses per year
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Subscribe To Our Newsletter & Stay Updated
